Covid 19 Vaccines: Novavax Gains FDA Authorization for Emergency Use

Covid 19 Vaccines: Novavax Updates and Availability

The US Food and Drug Administration has authorized an updated version of the Covid 19 vaccines, specifically the Novavax protein-based vaccine for those aged 12 and older. Doses of this vaccine are expected to hit shelves as early as next week.

Expert Insights on Vaccination

“The Covid 19 vaccines have had a tremendous positive impact on public health. Vaccination continues to be the most effective method for COVID-19 prevention,” stated Dr. Peter Marks from the FDA. He emphasized the ongoing risk posed by COVID-19 and urged eligible individuals to consider vaccination.

Comparing Vaccine Technologies

Unlike the rapidly produced mRNA vaccines from Pfizer and Moderna, Novavax's protein-based vaccine utilizes a more traditional method of stimulating the body’s immune system by introducing modified pieces of the virus. This approach focuses on the coronavirus spike protein and requires longer manufacturing times.

Current Recommendations and Availability

• The CDC suggests everyone aged 6 months and older receive both an updated Covid 19 vaccine and a flu shot.
• The FDA recently approved updated mRNA vaccines targeting the KP.2 strain.
• Novavax’s vaccine will be accessible in thousands of locations across the country.

With the SARS-CoV-2 virus levels recorded as “very high” nationally in wastewater, the situation underscores the importance of maintaining vaccination efforts. As testing diminishes, wastewater monitoring offers crucial insights into the virus's spread.